Related references
Note: Only part of the references are listed.Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo et al.
BONE MARROW TRANSPLANTATION (2020)
Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2019)
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial
Amber B. Clemmons et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting
Anncarin Svanberg et al.
ONCOLOGY (2015)
Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial
Thomas Schmitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Netupitant PET Imaging and ADME Studies in Humans
Tulla Spinelli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
Brian S. Choi et al.
LEUKEMIA & LYMPHOMA (2014)
Prevention of Nausea and Vomiting Associated with Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used with Highly Emetogenic Preparative Regimens
Patrick J. Stiff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects
Marigo Stathis et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting
Camilo Rojas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2012)
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Nicola Di Renzo et al.
SUPPORTIVE CARE IN CANCER (2011)
Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens
M. E. Trigg et al.
BONE MARROW TRANSPLANTATION (2008)
Share Paper
